Anchyra Partners LLC Acquires Shares of 5,665 Astrazeneca Plc $AZN

Anchyra Partners LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,665 shares of the company’s stock, valued at approximately $521,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AZN. Bank of America Corp DE lifted its position in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Astrazeneca by 2.3% during the 3rd quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after purchasing an additional 466,745 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after purchasing an additional 582,183 shares during the last quarter. Holocene Advisors LP raised its stake in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after purchasing an additional 1,807,565 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Astrazeneca by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock valued at $438,342,000 after purchasing an additional 660,569 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Down 1.3%

AZN stock opened at $187.30 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market capitalization of $290.48 billion, a PE ratio of 32.27, a price-to-earnings-growth ratio of 1.43 and a beta of 0.35. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio is 74.83%.

Analyst Ratings Changes

Several brokerages recently issued reports on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Barclays restated an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Weiss Ratings began coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Finally, Wall Street Zen lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $102.67.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.